Crystal form of 3-hydroxy-5-pregnane-20-one derivative, and preparation method therefor and use thereof
AssigneeTWi Biotechnology, Inc.
InventorsFei Liu, Gang Wu, Xianchao Li, Xiaobo Wang, Jinwei Liu
Life of this patent
Estimating the term…
Abstract
The present invention provides a crystal of a compound represented by formula I as a 3-hydroxy-5-pregnane-20-one derivative and a preparation method therefor. Specifically, the present invention provides novel crystal forms A-C of the compound represented by formula I and a preparation method therefor. The novel crystal forms of the compound represented by formula I of the present invention have excellent thermal stability and mechanical stability, the preparation process thereof is simple, and the novel crystal forms have an excellent industrial implementation potential.
Claims9
A crystalline form A of a compound of formula I and the X-ray powder diffraction pattern thereof shows characteristic peaks at following 2θ angles:
- 12.66±0.2°, 13.53±0.2°, 16.75±0.2° and 25.39±0.2°;
A crystalline form B of a compound of formula I and the X-ray powder diffraction pattern thereof shows characteristic peaks at following 2θ angles:
- 10.69±0.2°, 13.17±0.2°, 13.37±0.2° and 15.22±0.2°
A crystalline form C of a compound of formula I and the X-ray powder diffraction pattern thereof shows characteristic peaks at following 2θ angles:
- 6.77±0.2°, 7.08±0.2°, 8.34±0.2° and 12.46±0.2°;
A pharmaceutical composition, and said pharmaceutical composition comprises a crystalline form A, crystalline form B or crystalline form C of a compound of formula and optionally a pharmaceutically acceptable excipient;
- wherein the X-ray powder diffraction pattern of the crystalline form A shows characteristic peaks at following 2θ angles:
- 12.66±0.2°, 13.53±0.2°, 16.75±0.2° and 25.39±0.2°;
- or, the X-ray powder diffraction pattern of the crystalline form A further shows characteristic peaks at following 2θ angles:
- 11.96±0.2°, 12.66±0.2°, 13.53±0.2°, 14.51±0.2°, 16.75±0.2° and 25.39±0.2°;
- the X-ray powder diffraction pattern of the crystalline form B shows characteristic peaks at following 2θ angles:
- 10.69±0.2°, 13.17±0.2°, 13.37±0.2° and 15.22±0.2°;
- or, the X-ray powder diffraction pattern of the crystalline form B further shows characteristic peaks at following 2θ angles:
- 4.26±0.2°, 4.50±0.2°, 10.69±0.2°, 13.17±0.2°, 13.37±0.2°, and 15.22±0.2°;
- and
- the X-ray powder diffraction pattern of the crystalline form C shows characteristic peaks at following 2θ angles:
- 6.77±0.2°, 7.08±0.2°, 8.34±0.2° and 12.46±0.2°;
- or the X-ray powder diffraction pattern of the crystalline form C further shows characteristic peaks at following 2θ angles:
- 6.77±0.2°, 7.08±0.2°, 8.34±0.2°, 12.46±0.2°, 17.60±0.2° and 17.92±0.2°.
A method for treating or preventing a disorder of the central nervous system in a mammal, wherein said method comprises administering to the mammal a therapeutically effective amount of a compound of formula (I), crystalline form A, a pharmaceutical composition comprising the crystalline form A, crystalline form B, a pharmaceutical composition comprising the crystalline form B, crystalline form C, and a pharmaceutical composition comprising the crystalline form C;
- wherein the X-ray powder diffraction pattern of the crystalline form A shows characteristic peaks at following 2θ angles:
- 12.66±0.2°, 13.53±0.2°, 16.75±0.2° and 25.39±0.2°;
- or, the X-ray powder diffraction pattern of the crystalline form A further shows characteristic peaks at following 2θ angles:
- 11.96±0.2°, 12.66±0.2°, 13.53±0.2°, 14.51±0.2°, 16.75±0.2° and 25.39±0.2°;
- the X-ray powder diffraction pattern of the crystalline form B shows characteristic peaks at following 2θ angles:
- 10.69±0.2°, 13.17±0.2°, 13.37±0.2° and 15.22±0.2°;
- or, the X-ray powder diffraction pattern of the crystalline form B further shows characteristic peaks at following 2θ angles:
- 4.26±0.2°, 4.50±0.2°, 10.69±0.2°, 13.17±0.2°, 13.37±0.2°, and 15.22±0.2°;
- and
- the X-ray powder diffraction pattern of the crystalline form C shows characteristic peaks at following 2θ angles:
- 6.77±0.2°, 7.08±0.2°, 8.34±0.2° and 12.46±0.2°;
- or the X-ray powder diffraction pattern of the crystalline form C further shows characteristic peaks at following 20 angles:
- 6.77±0.2°, 7.08±0.2°, 8.34±0.2°, 12.46±0.2°, 17.60±0.2° and 17.92±0.2°.
Dependencies are inferred from the claim text.